PharVision Advisers’s Uranium Royalty Corp UROY Stock Holding History

PharVision Advisers’s Portfolio UROY Stock Details UROY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-12,612	Closed	-$46K	–	133
2026 Q1	$46K	Buy	+12,612	New	+$51.5K	0.47%	89

Other funds holding UROY

Mirae Asset Global ETFs Holdings Causeway Bay, Hong Kong $83.9B AUM 60.43% 1-Year Est. Return

CenterBook Partners Greenwich, Connecticut $2.04B AUM 35.27% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

AAG

Accordant Advisory Group Annapolis, Maryland $148M AUM 23.8% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Sprott Inc Toronto, Ontario, Canada $3.15B AUM 70.1% 1-Year Est. Return

Simcoe Capital Spokane, Washington $164M AUM

Vident Advisory Alpharetta, Georgia $13.9B AUM 53.47% 1-Year Est. Return

PharVision Advisers's UROY Position: Q2 2026 in Review

PharVision Advisers sold out of Uranium Royalty Corp (UROY) in Q2 2026, closing a stake of 12,612 shares — an estimated $46K sold.

PharVision Advisers first reported a position in UROY in Q1 2026 and held it in 1 quarter. The position peaked at $46K in Q1 2026. 112 funds tracked by Wall St. Rank hold UROY as of Q2 2026.

PharVision Advisers reported no remaining Uranium Royalty Corp position as of Q2 2026 after selling out during the quarter.
PharVision Advisers sold 12,612 Uranium Royalty Corp shares in Q2 2026, an estimated $46K.
PharVision Advisers first reported a position in Uranium Royalty Corp in Q1 2026 and held it in 1 quarter.
PharVision Advisers's Uranium Royalty Corp position peaked at $46K in Q1 2026.
112 funds tracked by Wall St. Rank held Uranium Royalty Corp as of Q2 2026.

Based on PharVision Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.